About Fusion Antibodies
Fusion Antibodies is a company based in Belfast (United Kingdom) founded in 2001. Fusion Antibodies has raised $2.5 million across 4 funding rounds from investors including Invest Northern Ireland, Crescent Capital and Qubis. Fusion Antibodies offers products and services including Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development. Fusion Antibodies operates in a competitive market with competitors including SSI Strategy, August Research, ProductLife Group, Health Decisions and Phastar, among others.
- Headquarter Belfast, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fusion Antibodies Plc
-
Annual Revenue
$2.55 M (USD)72.98as on Mar 31, 2025
-
Net Profit
-$2.21 M (USD)23.05as on Mar 31, 2025
-
EBITDA
-$2.16 M (USD)18.66as on Mar 31, 2025
-
Total Equity Funding
$2.5 M (USD)
in 4 rounds
-
Latest Funding Round
$1.77 M (USD), Post-IPO
Feb 14, 2024
-
Investors
Invest Northern Ireland
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Fusion Antibodies
Fusion Antibodies is a publicly listed company on the LSE with ticker symbol FAB in UK, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Fusion Antibodies
Fusion Antibodies offers a comprehensive portfolio of products and services, including Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development.
Service for humanizing antibodies to reduce immunogenicity for therapeutics.
Process to reformat antibodies for improved functionality and production.
Technique to enhance antibody binding affinity for better efficacy.
Creation of stable cell lines for antibody production and testing.
People of Fusion Antibodies
Unlock access to complete
Funding Insights of Fusion Antibodies
Fusion Antibodies has successfully raised a total of $2.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $1.77 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fusion Antibodies
Fusion Antibodies has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Invest Northern Ireland, Crescent Capital and Qubis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Qubis is engaged in commercializing academic research from Queen's University.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Fusion Antibodies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fusion Antibodies
Investment portfolio details for Fusion Antibodies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Fusion Antibodies
Detailed financials for Fusion Antibodies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fusion Antibodies Comparisons
Peer comparison for Fusion Antibodies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fusion Antibodies
Fusion Antibodies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SSI Strategy, August Research, ProductLife Group, Health Decisions and Phastar, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmacovigilance and medical affairs services are offered for drug development.
|
|
| Locked | Locked | Locked |
Clinical trial services are offered in Central and Eastern Europe.
|
|
| Locked | Locked | Locked |
Regulatory and pharmacovigilance support is provided for product lifecycles.
|
|
| Locked | Locked | Locked |
CRO focused on clinical trial services for data management, monitoring and biostatistics
|
|
| Locked | Locked | Locked |
Statistical consulting and data management for clinical trials are offered.
|
Detailed competitors of Fusion Antibodies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fusion Antibodies
Complete news archive for Fusion Antibodies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fusion Antibodies
Fusion Antibodies was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Fusion Antibodies is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.
Adrian Kinkaid is the current CEO of Fusion Antibodies.
Fusion Antibodies is a funded company, having raised a total of $2.5M across 4 funding rounds to date.
Annual revenue of Fusion Antibodies is $2.55M as on Mar 31, 2025.
Founded in 2001 and based in Belfast, United Kingdom, Fusion Antibodies operates as a contract research organization in the biotechnology sector. Services encompass antibody sequencing, humanization, stable cell line development, engineering, monoclonal antibody production, and transient protein expression. Two proprietary antibodies are currently in clinical and preclinical trials, supporting drug discovery and development processes.
Fusion Antibodies's top competitors include SSI Strategy, ProductLife Group and Health Decisions.
Fusion Antibodies offers Antibody Humanization, Antibody Reformatting, Affinity Maturation, and Cell Line Development.
Yes, Fusion Antibodies is publicly traded on LSE under the ticker symbol FAB.
Fusion Antibodies has 4 investors. Key investors include Invest Northern Ireland, Crescent Capital, Qubis, and Viridian Investment Partners.
The ticker symbol of Fusion Antibodies is FAB on LSE.